An expedient, ionic liquid mediated multi-component synthesis of novel piperidone grafted cholinesterase enzymes inhibitors and their molecular modeling study

European Journal of Medicinal Chemistry

Volumn 67, Issue , 2013, Pages 221-229

  Basiri, Alireza ^a   Murugaiyah, Vikneswaran ^a   Osman, Hasnah ^b   Kumar, Raju Suresh ^c   Kia, Yalda ^b   Awang, Khalijah Binti ^d   Ali, Mohamed Ashraf ^e  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b SCHOOL OF PHYSICS   (Malaysia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d UNIVERSITY OF MALAYA   (Malaysia)

^e INSTITUTE FOR RESEARCH IN MOLECULAR MEDICINE INFORMM   (Malaysia)

Author keywords

AChE; BChE; Ionic liquid; Molecular modeling; Multi component reaction

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; DONEPEZIL; GALANTAMINE; IONIC LIQUID; PIPERIDONE DERIVATIVE;

ARTICLE; CRYSTAL STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; MOLECULAR MODEL;

ACHE; BCHE; IONIC LIQUID; MOLECULAR MODELING; MULTI-COMPONENT REACTION;

ANIMALS; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IONIC LIQUIDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PIPERIDONES; STRUCTURE-ACTIVITY RELATIONSHIP; TORPEDO;

EID: 84882561082     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.06.054     Document Type: Article

References (35)

1. N.L. Batsch, M.S. Mittleman, World Alzheimer's Report 2012, World Alzheimer's Soceity, 2012.
2. J. Hardy, Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal, J. Alzheimers Dis. 9 (2006) 151-153. (Pubitemid 44253307)
3. C. Geula, M.M. Mesulam, Cholinesterases and the pathology of Alzheimer disease, Alzheimer Dis. Assoc. Disord. 9 (1995) 23-28.
4. A. Martorana, Z. Esposito, G. Koch, Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease? CNS Neurosci. Ther. 16 (2010) 235-245.
5. M. Farlow, M. Miller, V. Pejovic, Treatment options in Alzheimer's disease: maximizing benefit, managing expectations, Dement. Geriatr. Cogn. Disord. 25 (2008) 408-422. (Pubitemid 351630074)
6. G. Benzi, A. Moretti, Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? Eur. J. Pharm. Sci. 346 (1998) 1-13. (Pubitemid 28197082)
7. N. Tabet, Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing, Age Ageing 35 (2006) 336-338. (Pubitemid 43941799)
8. E. Giacobini, Cholinesterase inhibitors: new roles and therapeutic alternatives, Pharmacol. Res. 50 (2004) 433.
9. N. Greig, T. Utsuki, D. Ingram, Y. Wang, G. Pepeu, C. Scali, Q. Yu, J. Mamczarz, H. Holloway, T. Giordano, D. Chen, K. Furukawa, K. Sambamurti, A. Brossi, D. Lahiri, Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent, Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 17213-17218. (Pubitemid 41692709)
10. W. Xie, J.A. Stribley, A. Chatonnet, P.J. Wilder, A. Rizzino, R.D. McComb, P. Taylor, S.H. Hinrichs, O. Lockridge, Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase, J. Pharmacol. Exp. Ther. 293 (2000) 896-902. (Pubitemid 30417856)
11. C. Holmes, C. Ballard, D. Lehmann, A. David Smith, H. Beaumont, I.N. Day, M. Nadeem Khan, S. Lovestone, M. McCulley, C.M. Morris, D.G. Munoz, K. O'Brien, C. Russ, T. Del Ser, D. Warden, Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation, J. Neurol. Neurosurg. Psychiatry 76 (2005) 640-643. (Pubitemid 40569672)
12. D.B. Kitchen, H. Decornez, J.R. Furr, J. Bajorath, Docking and scoring in virtual screening for drug discovery: methods and applications, Nat. Rev. Drug Discov. 3 (2004) 935-949. (Pubitemid 39529931)
13. J.L. Sussman, M. Harel, F. Frolow, C. Oefner, A. Goldman, L. Toker, I. Silman, Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein, Science 253 (1991) 872-879. (Pubitemid 21917225)
14. M. Harel, D.M. Quinn, H.K. Nair, I. Silman, J.L. Sussman, The X-ray structure of a transition state analog complex reveals the molecular origins of the catalytic power and substrate specificity of acetylcholinesterase, J. Am. Chem. Soc. 118 (1996) 2340-2346. (Pubitemid 26124248)
15. M. Harel, I. Schalk, L. Ehret-Sabatier, F. Bouet, M. Goeldner, C. Hirth, P.H. Axelsen, I. Silman, J.L. Sussman, Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase, Proc. Natl. Acad. Sci. U.S.A 90 (1993) 9031-9035. (Pubitemid 23306445)
16. L. Pezzementi, F. Nachon, A. Chatonnet, Evolution of acetylcholinesterase and butyrylcholinesterase in the vertebrates: an atypical butyrylcholinesterase from the Medaka Oryzias latipes, PLoS One 6 (2011) e17396.
17. A.N. Çokuǧraş, Butyrylcholinesterase: structure and physiological importance, Turk. J. Biochem. 28 (2003) 54-61.
18. N. Isambert, M.M.S. Duque, J.C. Plaquevent, Y. Enisson, J. Rodriguez, T. Constantieux, Multicomponent reactions and ionic liquids: a perfect synergy for eco-compatible heterocyclic synthesis, Chem. Soc. Rev. 40 (2011) 1347-1357.
19. M. Petkovic, K.R. Seddon, L.P.N. Rebelo, C.S. Pereira, Ionic liquids: a pathway to environmental acceptability, Chem. Soc. Rev. 40 (2011) 1383-1403.
20. K.S. Atwal, G.C. Rovnyak, B.C. O'Reilly, J. Schwartz, Substituted 1,4-dihydropyrimidines. 3. Synthesis of selectively functionalized 2-hetero-1, 4-dihydropyrimidines, J. Org. Chem. 54 (1989) 5898-5907. (Pubitemid 20066313)
21. G.C. Rovnyak, K.S. Atwal, A. Hedberg, S.D. Kimball, S. Moreland, J.Z. Gougoutas, B.C. O'Reilly, J. Schwartz, M.F. Malley, Dihydropyrimidine calcium channel blockers. 4. Basic 3-substituted-4-aryl-1,4-dihydropyrimidine-5- carboxylic acid esters. Potent antihypertensive agents, J. Med. Chem. 35 (1992) 3254-3263.
22. D. Nagarathnam, S.W. Miao, B. Lagu, G. Chiu, J. Fang, T.G.M. Dhar, J. Zhang, S. Tyagarajan, M.R. Marzabadi, F. Zhang, Design and synthesis of novel α1a adrenoceptor-selective antagonists. 1. Structure-activity relationship in dihydropyrimidinones, J. Med. Chem. 42 (1999) 4764-4777.
23. C.O. Kappe, Biologically active dihydropyrimidones of the Biginelli-type - a literature survey, Eur. J. Med. Chem. 35 (2000) 1043-1052. (Pubitemid 32050011)
24. G.P. Black, S.J. Coles, A. Hizi, A.G. Howard-Jones, M.B. Hursthouse, A.T. McGown, S. Loya, C.G. Moore, P.J. Murphy, N.K. Smith, Synthesis and biological activity of analogues of ptilomycalin A, Tetrahedron Lett. 42 (2001) 3377-3381. (Pubitemid 32373213)
25. T.U. Mayer, T.M. Kapoor, S.J. Haggarty, R.W. King, S.L. Schreiber, T.J. Mitchison, Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen, Science 286 (1999) 971-974.
26. A.D.K. Patil, N.V. Kokke, W.C. Bean, Novel alkaloids from the sponge Batzella sp.: inhibitors of HIV gp120-human CD4 binding, J. Org. Chem. 60 (1995) 1182-1188.
27. T. Mohamed, P.P. Rao, Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors, Bioorg. Med. Chem. Lett. 20 (2010) 3606-3609.
28. T. Mohamed, X. Zhao, L.K. Habib, J. Yang, P.P. Rao, Design, synthesis and structure - activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and Aβ-aggregation inhibitors, Bioorg. Med. Chem. 19 (2011) 2269-2281.
29. T. Mohamed, J.C. Yeung, M.S. Vasefi, M.A. Beazely, P.P. Rao, Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template, Bioorg. Med. Chem. Lett. 22 (2012) 4707-4712.
30. A. Basiri, V. Murugaiyah, H. Osman, R.S. Kumar, Y. Kia, M.A. Ali, Microwave assisted synthesis, cholinesterase enzymes inhibitory activities and molecular docking studies of new pyridopyrimidine derivatives, Bioorg. Med. Chem. 21 (2013) 3022-3031.
31. J. Figueiredo, M. Ismael, J. Pinheiro, A. Silva, J. Justino, F. Silva, M. Goulart, D. Mira, M. Araújo, R. Campoy, Facile synthesis of oxo-/thioxopyrimidines and tetrazoles C-C linked to sugars as novel non-toxic antioxidant acetylcholinesterase inhibitors, Carbohydr. Res. 347 (2012) 47-54.
32. Crystallographic data (excluding structure factors) for pyridopyrimidine-2-thiones 7b in this letter have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication number CCDC 936212. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44(0)1223-336033 or e-mail: deposit@ccdc.cam.ac.uk].
33. J. Cheung, M.J. Rudolph, F. Burshteyn, M.S. Cassidy, E.N. Gary, J. Love, M.C. Franklin, J.J. Height, Structures of human acetylcholinesterase in complex with pharmacologically important ligands, J. Med. Chem. 55 (2012) 10286.
34. Y. Nicolet, O. Lockridge, P. Masson, J.C. Fontecilla-Camps, F. Nachon, Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products, J. Biol. Chem. 278 (2003) 41141-41147. (Pubitemid 37280939)
35. T. Ahmed, A.H. Gilani, Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease, Pharmacol. Biochem. Behav. 91 (2009) 554-559.